SCHEMBL3485402

SCHEMBL3485402

CC(NC(=O)c1ncc(-c2cccc(C(F)(F)F)c2)cc1O)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
EGLN1 Q9GZT9 7/20 0.48
GRIN2B Q13224 9/20 0.47
GRIN1 Q05586 8/20 0.47
EGLN3 Q9H6Z9 3/20 0.46
VEGFA P15692 3/20 0.45
FLT1 P17948 3/20 0.45
TET3 O43151 1/20 0.45
BBOX1 O75936 1/20 0.45
ASPH Q12797 1/20 0.45
TET2 Q6N021 1/20 0.45
KDM8 Q8N371 1/20 0.45
OGFOD1 Q8N543 1/20 0.45
TET1 Q8NFU7 1/20 0.45
HIF1AN Q9NWT6 1/20 0.45
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CG P48736 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485401 0.90 EGLN1 (0.48) EGLN1GRIN2BGRIN1EGLN3VEGFA
SCHEMBL3485322 0.89 CNR2 (0.47) EGLN1GRIN2BGRIN1EGLN3VEGFA
SCHEMBL3485356 0.89 EGLN1 (0.49) EGLN1GRIN2BGRIN1EGLN3VEGFA
SCHEMBL3485269 0.89 GRIN2B (0.47) EGLN1GRIN2BGRIN1EGLN3VEGFA
SCHEMBL3485085 0.87 GRIN2B (0.51) EGLN1GRIN2BGRIN1EGLN3VEGFA
SCHEMBL3485380 0.86 EGLN1 (0.64) EGLN1GRIN2BEGLN3VEGFAFLT1
SCHEMBL1921446 0.83 EGLN1 (0.65) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL3484863 0.81 EGLN1 (0.53) EGLN1GRIN2BGRIN1EGLN3VEGFA
SCHEMBL29056831 0.80 EGLN1 (0.47) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL1921240 0.80 EGLN1 (0.75) EGLN1EGLN3VEGFAFLT1TET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160009648-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2016-01-14 US claimed
US-8343952-B2 Prolyl hydroxylase inhibitors and methods of use AKEBIA THERAPEUTICS INC. (US) 2013-01-01 US claimed
US-20100331303-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE AKEBIA THERAPEUTICS, INC. 2010-12-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009648-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A KDM4E 562/4885SMN1; SMN2 4157/4885EGLN1 6/4885
US-20100331303-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A KDM4E 562/4885SMN1; SMN2 4157/4885EGLN1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.